Literature DB >> 29117545

Resistance Is Futile: Targeting Mitochondrial Energetics and Metabolism to Overcome Drug Resistance in Cancer Treatment.

Claudie Bosc1, Mary A Selak1, Jean-Emmanuel Sarry2.   

Abstract

Metabolism is a key regulator of cancer biology; however, its role in therapeutic resistance has remained largely unresolved. Several new studies disclose that mitochondrial metabolism and oxidative phosphorylation at least in part drive chemoresistance in cancer and thus have important implications for targeted and more effective chemotherapies.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29117545     DOI： 10.1016/j.cmet.2017.10.013

Source DB:  PubMed          Journal:  Cell Metab        ISSN： 1550-4131            Impact factor:   27.287


  49 in total

1.  1,3,4-oxadiazole/chalcone hybrids: Design, synthesis, and inhibition of leukemia cell growth and EGFR, Src, IL-6 and STAT3 activities.

Authors:  Marwa Ali A Fathi; Amer Ali Abd El-Hafeez; Dalia Abdelhamid; Samar H Abbas; Monica M Montano; Mohamed Abdel-Aziz
Journal:  Bioorg Chem       Date:  2018-11-22       Impact factor: 5.275

2.  Repurposing FDA approved drugs inhibiting mitochondrial function for targeting glioma-stem like cells.

Authors:  Sandipan Datta; Thomas Sears; Gino Cortopassi; Kevin Woolard; James M Angelastro
Journal:  Biomed Pharmacother       Date:  2020-12-08       Impact factor: 6.529

3.  Multiomic Profiling of Tyrosine Kinase Inhibitor-Resistant K562 Cells Suggests Metabolic Reprogramming To Promote Cell Survival.

Authors:  Brett M Noel; Steven B Ouellette; Laura Marholz; Deborah Dickey; Connor Navis; Tzu-Yi Yang; Vinh Nguyen; Sarah J Parker; David Bernlohr; Zohar Sachs; Laurie L Parker
Journal:  J Proteome Res       Date:  2019-02-21       Impact factor: 4.466

4.  A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia.

Authors:  Timothy S Pardee; Rebecca G Anderson; Kristin M Pladna; Scott Isom; Lais P Ghiraldeli; Lance D Miller; Jeff W Chou; Guangxu Jin; Wei Zhang; Leslie R Ellis; Dmitriy Berenzon; Dianna S Howard; David D Hurd; Megan Manuel; Sarah Dralle; Susan Lyerly; Bayard L Powell
Journal:  Clin Cancer Res       Date:  2018-02-06       Impact factor: 12.531

5.  Perimitochondrial Enzymatic Self-Assembly for Selective Targeting the Mitochondria of Cancer Cells.

Authors:  Hongjian He; Xinyi Lin; Jiaqi Guo; Jiaqing Wang; Bing Xu
Journal:  ACS Nano       Date:  2020-05-14       Impact factor: 15.881

6.  The mitophagy effector FUNDC1 controls mitochondrial reprogramming and cellular plasticity in cancer cells.

Authors:  Jie Li; Ekta Agarwal; Irene Bertolini; Jae Ho Seo; M Cecilia Caino; Jagadish C Ghosh; Andrew V Kossenkov; Qin Liu; Hsin-Yao Tang; Aaron R Goldman; Lucia R Languino; David W Speicher; Dario C Altieri
Journal:  Sci Signal       Date:  2020-07-28       Impact factor: 8.192

Review 7.  Mitochondria in cancer metabolism, an organelle whose time has come?

Authors:  Rebecca G Anderson; Lais P Ghiraldeli; Timothy S Pardee
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2018-05-26       Impact factor: 10.680

8.  Targeting tumor phenotypic plasticity and metabolic remodeling in adaptive cross-drug tolerance.

Authors:  Aaron Goldman; Sachin Khiste; Elizaveta Freinkman; Andrew Dhawan; Biswanath Majumder; Jayanta Mondal; Anthony B Pinkerton; Elliot Eton; Ragini Medhi; Vineethkrishna Chandrasekar; M Mamunur Rahman; Takaharu Ichimura; Kodaganur S Gopinath; Pradip Majumder; Mohammad Kohandel; Shiladitya Sengupta
Journal:  Sci Signal       Date:  2019-08-20       Impact factor: 8.192

9.  Mitochondrial structural alterations in ovarian cancer patient-derived xenografts resistant to cisplatin.

Authors:  Francesca Ricci; Alessandro Corbelli; Roberta Affatato; Rosaria Chilà; Michela Chiappa; Laura Brunelli; Robert Fruscio; Roberta Pastorelli; Fabio Fiordaliso; Giovanna Damia
Journal:  Am J Cancer Res       Date:  2021-05-15       Impact factor: 6.166

10.  Modulation of redox metabolism negates cancer-associated fibroblasts-induced treatment resistance in a heterotypic 3D culture platform of pancreatic cancer.

Authors:  Mans Broekgaarden; Sriram Anbil; Anne-Laure Bulin; Girgis Obaid; Zhiming Mai; Yan Baglo; Imran Rizvi; Tayyaba Hasan
Journal:  Biomaterials       Date:  2019-08-12       Impact factor: 12.479
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.